Regulatory round-up: 6 July 2026

Regulators in the USA, Japan, the UK, Switzerland, Australia and several other major international markets have issued a mix of safety statements, review updates, guidance changes, compliance notices and regulatory procedure updates over the past week, reflecting continued activity across pharmacovigilance, labelling, medicine supply, biosimilars, e-labelling and unauthorized products.

The latest round-up includes an FDA statement on neurological complications linked to general anesthesia in a genetically defined patient group, PMDA review and safety updates, MHRA guidance and supply-control changes, Swissmedic authorization and product-information updates, TGA safety alerts and adopted guidelines, and further updates from Singapore, Brazil, South Korea, Saudi Arabia, India, Indonesia, France and Turkey. The table below summarizes official human medicines regulatory updates from the past seven days.